{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:52:45Z","timestamp":1780879965702,"version":"3.54.1"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001403","name":"Indian Institute of Technology Kanpur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001403","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["09\/0719(18202)\/2024-EMR-I"],"award-info":[{"award-number":["09\/0719(18202)\/2024-EMR-I"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013225","name":"Academy of Scientific and Innovative Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006464","name":"Birla Institute of Technology and Science, Pilani","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006464","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.lfs.2025.123536","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T12:24:54Z","timestamp":1741263894000},"page":"123536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A critique review of fetal hemoglobin modulators through targeting epigenetic regulators for the treatment of sickle cell disease"],"prefix":"10.1016","volume":"369","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6798-855X","authenticated-orcid":false,"given":"Chandu","family":"Ala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0901-2513","authenticated-orcid":false,"given":"Sivaprakash","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2319-8297","authenticated-orcid":false,"given":"Chandra Sekhar","family":"Kondapalli Venkata Gowri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3680-1577","authenticated-orcid":false,"given":"Murugesan","family":"Sankaranarayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2025.123536_bb0005","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.disamonth.2017.12.003","article-title":"Sickle cell disease; an overview of the disease and its systemic effects","volume":"64","author":"Alrayyes","year":"2018","journal-title":"Dis. Mon."},{"key":"10.1016\/j.lfs.2025.123536_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202400381","article-title":"A critical review of therapeutic interventions in sickle cell disease: progress and challenges","volume":"357","author":"Ala","year":"2024","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.lfs.2025.123536_bb0015","unstructured":"Sickle Cell Disease | WHO | Regional Office for Africa, (n.d.). https:\/\/www.afro.who.int\/health-topics\/sickle-cell-disease (accessed January 1, 2025)."},{"key":"10.1016\/j.lfs.2025.123536_bb0020","unstructured":"Data and Statistics on Sickle Cell Disease | Sickle Cell Disease (SCD) | CDC, (n.d.). https:\/\/www.cdc.gov\/sickle-cell\/data\/index.html (accessed January 2, 2025)."},{"key":"10.1016\/j.lfs.2025.123536_bb0025","series-title":"Thinking Globally, Acting Locally: India\u2019s Sickle Cell Mission as a Model for the World","author":"M.M. @JasonPayneMD Jason Payne","year":"2024"},{"key":"10.1016\/j.lfs.2025.123536_bb0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4939-7299-9_2","article-title":"Genetic basis and genetic modifiers of \u03b2-thalassemia and sickle cell disease","volume":"1013","author":"Thein","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.lfs.2025.123536_bb0035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.lfs.2025.123536_bb0040","author":"Cowled"},{"key":"10.1016\/j.lfs.2025.123536_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2018.00125","article-title":"Erythrocytes and vascular function: oxygen and nitric oxide","volume":"9","author":"Helms","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.lfs.2025.123536_bb0050","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1172\/JCI89741","article-title":"Intravascular hemolysis and the pathophysiology of sickle cell disease","volume":"127","author":"Kato","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2025.123536_bb0055","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1100\/tsw.2008.157","article-title":"Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches","volume":"8","author":"Steinberg","year":"2008","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.lfs.2025.123536_bb0060","first-page":"364","article-title":"Sickle cell disease; a general overview","volume":"62","author":"Schnog","year":"2004","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.lfs.2025.123536_bb0065","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","article-title":"Sickle cell disease","volume":"390","author":"Ware","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.lfs.2025.123536_bb0070","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1182\/bloodadvances.2022008965","article-title":"The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease","volume":"7","author":"Cronin","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.lfs.2025.123536_bb0075","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2025.123536_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70082","article-title":"What\u2019s wrong with drug development for sickle cell disease?","volume":"9","author":"Brousse","year":"2025","journal-title":"HemaSphere"},{"key":"10.1016\/j.lfs.2025.123536_bb0085","series-title":"React. Wkly. 2028","first-page":"1","article-title":"All lots of voxelotor withdrawn in all markets","year":"2024"},{"key":"10.1016\/j.lfs.2025.123536_bb0090","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1097\/MS9.0000000000002146","article-title":"Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR\/Cas9 gene therapy for sickle cell disease","volume":"86","author":"Singh","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.lfs.2025.123536_bb0095","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.944204","article-title":"Editorial: first regulatory approvals for CRISPR-Cas9 therapeutic gene editing for sickle cell disease and transfusion-dependent \u03b2-thalassemia","volume":"30","author":"Parums","year":"2024","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.lfs.2025.123536_bb0100","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/bjh.15038","article-title":"Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies","volume":"180","author":"Vinjamur","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/biom13030413","article-title":"The sickle-cell fiber revisited","volume":"13","author":"Bishop","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.lfs.2025.123536_bb0110","doi-asserted-by":"crossref","first-page":"31563","DOI":"10.1016\/S0021-9258(18)31730-7","article-title":"Role of hydrophobicity of phenylalanine beta 85 and leucine beta 88 in the acceptor pocket for valine beta 6 during hemoglobin S polymerization","volume":"269","author":"Adachi","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2025.123536_bb0115","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1182\/blood-2017-02-765891","article-title":"Treating sickle cell disease by targeting HbS polymerization","volume":"129","author":"Eaton","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0120","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0022-2836(85)90174-3","article-title":"Kinetics of sickle hemoglobin polymerization","volume":"183","author":"Ferrone","year":"1985","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.lfs.2025.123536_bb0125","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41598-024-52476-8","article-title":"Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action","volume":"14","author":"Suhail","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2025.123536_bb0130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.exphem.2004.11.007","article-title":"Control of globin gene expression during development and erythroid differentiation","volume":"33","author":"Stamatoyannopoulos","year":"2005","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0135","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.5045\/br.2021.2020332","article-title":"Molecular basis and diagnosis of thalassemia","volume":"56","author":"Lee","year":"2021","journal-title":"Blood Res."},{"key":"10.1016\/j.lfs.2025.123536_bb0140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminhematol.2020.12.001","article-title":"Epigenetic regulation of hemoglobin switching in non-human primates","volume":"58","author":"Molokie","year":"2021","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0145","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12881-020-01059-1","article-title":"Identifying genetic variants and pathways associated with extreme levels of fetal hemoglobin in sickle cell disease in Tanzania","volume":"21","author":"Nkya","year":"2020","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.lfs.2025.123536_bb0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2011-03-325258","article-title":"Fetal hemoglobin in sickle cell anemia","volume":"118","author":"Akinsheye","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0155","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood-2010-11-316893","article-title":"Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities","volume":"117","author":"Wilber","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10059-012-0048-8","article-title":"Chromatin loop formation in the \u03b2-globin locus and its role in globin gene transcription","volume":"34","author":"Kim","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.lfs.2025.123536_bb0165","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/genes14030577","article-title":"Epigenetic regulation of \u03b2-globin genes and the potential to treat hemoglobinopathies through epigenome editing","volume":"14","author":"Fontana","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.lfs.2025.123536_bb0170","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1073\/pnas.0711566105","article-title":"Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia","volume":"105","author":"Uda","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.lfs.2025.123536_bb0175","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/jhg.2011.12","article-title":"Genome-wide association study identifies genetic variants influencing F-cell levels in sickle-cell patients","volume":"56","author":"Bhatnagar","year":"2011","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.lfs.2025.123536_bb0180","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.cell.2018.03.016","article-title":"Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2025.123536_bb0185","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gde.2015.08.001","article-title":"Hemoglobin switching\u2019s surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin","volume":"33","author":"Bauer","year":"2015","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.lfs.2025.123536_bb0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/nyas.13024","article-title":"Regulation of the fetal hemoglobin silencing factor BCL11A","volume":"1368","author":"Basak","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.lfs.2025.123536_bb0195","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.hoc.2022.12.001","article-title":"Molecular basis and genetic modifiers of thalassemia","volume":"37","author":"Tesio","year":"2023","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.lfs.2025.123536_bb0200","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jmb.2019.10.007","article-title":"The methyl-CpG-binding domain 2 and 3 proteins and formation of the nucleosome remodeling and deacetylase complex","volume":"432","author":"Leighton","year":"2020","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.lfs.2025.123536_bb0205","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.molcel.2020.11.006","article-title":"ZNF410 uniquely activates the NuRD component CHD4 to silence fetal hemoglobin expression","volume":"81","author":"Lan","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.lfs.2025.123536_bb0210","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2020.11.007","article-title":"Epigenetic activities in erythroid cell gene regulation","volume":"58","author":"Wang","year":"2021","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0215","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.bbagrm.2017.01.014","article-title":"Epigenetic interplay at the \u03b2-globin locus","volume":"1860","author":"Lee","year":"2017","journal-title":"Biochim. Biophys. Acta-Gene Regul. Mech."},{"key":"10.1016\/j.lfs.2025.123536_bb0220","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1139\/bcb-2018-0303","article-title":"LRF acts as an activator and repressor of the human \u03b2-like globin gene transcription in a developmental stage dependent manner","volume":"97","author":"Kang","year":"2019","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.lfs.2025.123536_bb0225","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.aad3312","article-title":"Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin","volume":"351","author":"Masuda","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.lfs.2025.123536_bb0230","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-021-24402-3","article-title":"Reactivation of a developmentally silenced embryonic globin gene","volume":"12","author":"King","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2025.123536_bb0235","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay9392","article-title":"Editing a \u03b3-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype","volume":"6","author":"Weber","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.lfs.2025.123536_bb0240","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0378-1119(00)00140-2","article-title":"Roles of the NFI\/CTF gene family in transcription and development","volume":"249","author":"Gronostajski","year":"2000","journal-title":"Gene"},{"key":"10.1016\/j.lfs.2025.123536_bb0245","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41588-022-01076-1","article-title":"Dual function NFI factors control fetal hemoglobin silencing in adult erythroid cells","volume":"54","author":"Qin","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lfs.2025.123536_bb0250","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s42003-023-05025-4","article-title":"Erythroid lineage chromatin accessibility maps facilitate identification and validation of NFIX as a fetal hemoglobin repressor","volume":"6","author":"Chaand","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.lfs.2025.123536_bb0255","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1182\/blood.2023022190","article-title":"Elevating fetal hemoglobin: recently discovered regulators and mechanisms","volume":"144","author":"Khandros","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0260","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.bbagrm.2016.10.002","article-title":"The regulation of human globin promoters by CCAAT box elements and the recruitment of NF-Y","volume":"1860","author":"Martyn","year":"2017","journal-title":"Biochim. Biophys. Acta-Gene Regul. Mech."},{"key":"10.1016\/j.lfs.2025.123536_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047175","article-title":"NF-Y recruits both transcription activator and repressor to modulate tissue- and developmental stage-specific expression of human \u03b3-globin gene","volume":"7","author":"Zhu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2025.123536_bb0270","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/s41588-021-00904-0","article-title":"Activation of \u03b3-globin gene expression by GATA1 and NF-Y in hereditary persistence of fetal hemoglobin","volume":"53","author":"Doerfler","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lfs.2025.123536_bb0275","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jgg.2024.07.004","article-title":"Gene therapy and gene editing strategies in inherited blood disorders","volume":"51","author":"Song","year":"2024","journal-title":"J. Genet. Genomics"},{"key":"10.1016\/j.lfs.2025.123536_bb0280","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41588-021-00798-y","article-title":"Transcription factor competition at the \u03b3-globin promoters controls hemoglobin switching","volume":"53","author":"Liu","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lfs.2025.123536_bb0285","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","article-title":"Regulation of erythropoiesis by hypoxia-inducible factors","volume":"27","author":"Haase","year":"2013","journal-title":"Blood Rev."},{"key":"10.1016\/j.lfs.2025.123536_bb0290","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41586-022-05312-w","article-title":"Activation of \u03b3-globin expression by hypoxia-inducible factor 1\u03b1","volume":"610","author":"Feng","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2025.123536_bb0295","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/14728222.2024.2367640","article-title":"Targeting HIF-1\u03b1 in sickle cell disease and cancer: unraveling therapeutic opportunities and risks","volume":"28","author":"Ubaid","year":"2024","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.lfs.2025.123536_bb0300","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1615\/CritRevOncog.2015012997","article-title":"Histone deacetylases and mechanisms of regulation of gene expression","volume":"20","author":"Chen","year":"2015","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.lfs.2025.123536_bb0305","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/ajh.24879","article-title":"SIRT1 activates the expression of fetal hemoglobin genes","volume":"92","author":"Dai","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0310","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ajh.24019","article-title":"Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation","volume":"90","author":"Esrick","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0315","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V74.1.454.454","article-title":"Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with Hb SS and beta thalassemia","volume":"74","author":"Perrine","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0320","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood.V72.6.1961.1961","article-title":"alpha-Amino-N-butyric acid stimulates fetal hemoglobin in the adult","volume":"72","author":"Constantoulakis","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0325","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood.V74.6.1963.1963","article-title":"On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC","volume":"74","author":"Constantoulakis","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0330","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM199301143280202","article-title":"A short-term trial of butyrate to stimulate fetal-globin-gene expression in the \u03b2-globin disorders","volume":"328","author":"Perrine","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2025.123536_bb0335","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.exphem.2005.08.007","article-title":"Hydroxamide derivatives of short-chain fatty acid have erythropoietic activity and induce \u03b3 gene expression in vivo","volume":"33","author":"Cao","year":"2005","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0340","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0301-472X(02)01030-5","article-title":"Hydroxamide derivatives of short-chain fatty acids are potent inducers of human fetal globin gene expression","volume":"31","author":"Skarpidi","year":"2003","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0345","first-page":"1790","article-title":"Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease","volume":"93","author":"Atweh","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0350","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajh.23306","article-title":"A phase 1\/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease","volume":"87","author":"Kutlar","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0355","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1124\/mol.107.036772","article-title":"Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia","volume":"72","author":"Mai","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.lfs.2025.123536_bb0360","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ajh.20676","article-title":"Histone deacetylase inhibitor FK228 is a potent inducer of human fetal hemoglobin","volume":"81","author":"Cao","year":"2006","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/428137","article-title":"FK228 analogues induce fetal hemoglobin in human erythroid progenitors","volume":"2012","author":"Makala","year":"2012","journal-title":"Anemia"},{"key":"10.1016\/j.lfs.2025.123536_bb0370","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2015-03-635391","article-title":"Phase 1\/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea","volume":"125","author":"Okam","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0375","doi-asserted-by":"crossref","first-page":"12617","DOI":"10.1073\/pnas.1006774107","article-title":"Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease","volume":"107","author":"Bradner","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2025.123536_bb0380","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1074\/jbc.M110.115725","article-title":"Histone deacetylase 9 activates \u03b3-globin gene expression in primary erythroid cells","volume":"286","author":"Muralidhar","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2025.123536_bb0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153767","article-title":"Chemical inhibition of histone deacetylases 1 and 2 induces fetal hemoglobin through activation of GATA2","volume":"11","author":"Shearstone","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2025.123536_bb0390","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.3390\/ijms21228828","article-title":"Structure-based inhibitor discovery of class I histone deacetylases (HDACs)","volume":"21","author":"Luo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.123536_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2021.102626","article-title":"Novel histone deacetylase inhibitor CT-101 induces \u03b3-globin gene expression in sickle erythroid progenitors with targeted epigenetic effects","volume":"93","author":"Junker","year":"2022","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.lfs.2025.123536_bb0400","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/bjh.15021","article-title":"Fetal haemoglobin induction in sickle cell disease","volume":"180","author":"Paikari","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0405","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2007-01-068635","article-title":"Developmental- and differentiation-specific patterns of human \u03b3- and \u03b2-globin promoter DNA methylation","volume":"110","author":"Mabaera","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0410","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.exphem.2010.10.003","article-title":"siDNMT1 increases \u03b3-globin expression in chemical inducer of dimerization (CID)\u2212 dependent mouse \u03b2YAC bone marrow cells and in baboon erythroid progenitor cell cultures","volume":"39","author":"Banzon","year":"2011","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0415","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.trsl.2014.05.002","article-title":"Epigenetic regulation of fetal globin gene expression in adult erythroid cells","volume":"165","author":"Ginder","year":"2015","journal-title":"Transl. Res."},{"key":"10.1016\/j.lfs.2025.123536_bb0420","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/j.seminhematol.2018.04.008","article-title":"Fetal hemoglobin induction by epigenetic drugs","volume":"55","author":"Lavelle","year":"2018","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0425","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1056\/NEJM198212093072401","article-title":"5-Azacytidine selectively increases \u03b3-globin synthesis in a patient with \u03b2 + thalassemia","volume":"307","author":"Ley","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2025.123536_bb0430","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood.V62.2.370.370","article-title":"5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia","volume":"62","author":"Ley","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0435","first-page":"475","article-title":"5-Azacytidine increases fetal hemoglobin production in a patient with sickle cell disease","volume":"134","author":"Dover","year":"1983","journal-title":"Prog. Clin. Biol. Res."},{"key":"10.1016\/j.lfs.2025.123536_bb0440","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1182\/blood.V66.3.527.527","article-title":"5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens","volume":"66","author":"Dover","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0445","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199309163291205","article-title":"Treatment with azacitidine of patients with end-stage \u03b2-thalassemia","volume":"329","author":"Lowrey","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2025.123536_bb0450","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1172\/JCI111731","article-title":"5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin","volume":"75","author":"Humphries","year":"1985","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2025.123536_bb0455","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2012-10-408021","article-title":"Clinical experience with fetal hemoglobin induction therapy in patients with \u03b2-thalassemia","volume":"121","author":"Musallam","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0460","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood.V96.7.2379","article-title":"2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia","volume":"96","author":"Koshy","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0465","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2003-05-1738","article-title":"Effects of 5-aza-2\u2032-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0470","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2141.2008.07027.x","article-title":"Clinical effectiveness of decitabine in severe sickle cell disease","volume":"141","author":"Saunthararajah","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0475","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2011-03-341909","article-title":"A pilot study of subcutaneous decitabine in \u03b2-thalassemia intermedia","volume":"118","author":"Olivieri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0480","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.exphem.2009.06.007","article-title":"Transcriptional activation of the \u03b3-globin gene in baboons treated with decitabine and in cultured erythroid progenitor cells involves different mechanisms","volume":"37","author":"Chin","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002382","article-title":"Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study","volume":"14","author":"Molokie","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.lfs.2025.123536_bb0490","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.3324\/haematol.2020.248658","article-title":"In vitro and in vivo induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor","volume":"106","author":"Gilmartin","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.lfs.2025.123536_bb0495","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1182\/bloodadvances.2022009558","article-title":"Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF","volume":"7","author":"Ibanez","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.lfs.2025.123536_bb0500","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3390\/ph15060753","article-title":"Pharmacological induction of fetal hemoglobin in \u03b2-thalassemia and sickle cell disease: an updated perspective","volume":"15","author":"Bou-Fakhredin","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.lfs.2025.123536_bb0505","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1096\/fj.13-242669","article-title":"Trans- criptional regulators Myb and BCL11A interplay with DNA methyltransferase 1 in developmental silencing of embryonic and fetal \u03b2-like globin genes","volume":"28","author":"Roosjen","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.lfs.2025.123536_bb0510","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/genes15050563","article-title":"Roles of nuclear orphan receptors TR2 and TR4 during hematopoiesis","volume":"15","author":"Myers","year":"2024","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.lfs.2025.123536_bb0515","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/07391102.2023.2199081","article-title":"Discovery of potent DNMT1 inhibitors against sickle cell disease using structural-based virtual screening, MM-GBSA and molecular dynamics simulation-based approaches","volume":"42","author":"Ala","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.lfs.2025.123536_bb0520","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.4155\/fmc-2017-0074","article-title":"Inhibition studies of DNA methyltransferases by maleimide derivatives of RG108 as non-nucleoside inhibitors","volume":"9","author":"Rondelet","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.lfs.2025.123536_bb0525","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/07391102.2023.2199081","article-title":"Discovery of potent DNMT1 inhibitors against sickle cell disease using structural-based virtual screening, MM-GBSA and molecular dynamics simulation-based approaches","volume":"42","author":"Ala","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.lfs.2025.123536_bb0530","doi-asserted-by":"crossref","first-page":"9028","DOI":"10.1021\/jm501134e","article-title":"Identifying novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual screening","volume":"57","author":"Chen","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2025.123536_bb0535","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood-2009-10-251116","article-title":"Identification of a PRMT5-dependent repressor complex linked to silencing of human fetal globin gene expression","volume":"116","author":"Rank","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0540","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nsmb.1568","article-title":"PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing","volume":"16","author":"Zhao","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.lfs.2025.123536_bb0545","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302254120","article-title":"MBD2a\u2013NuRD binds to the methylated \u03b3-globin gene promoter and uniquely forms a complex required for silencing of HbF expression","volume":"120","author":"Shang","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2025.123536_bb0550","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1479-5876-11-14","article-title":"Induction of human fetal hemoglobin expression by adenosine-2\u2032,3\u2032-dialdehyde","volume":"11","author":"He","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lfs.2025.123536_bb0555","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2019-130337","article-title":"A phase I\/II study to investigate the safety and clinical activity of the protein arginine methyltransferase 5 inhibitor GSK3326595 in subjects with myelodysplastic syndrome and acute myeloid leukemia","volume":"134","author":"Watts","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0560","doi-asserted-by":"crossref","first-page":"13180","DOI":"10.1080\/07391102.2023.2184172","article-title":"In silico analysis of marine natural product for protein arginine methyltransferase 5(PRMT5) inhibitors based on pharmacophore and molecular docking","volume":"41","author":"Luo","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.lfs.2025.123536_bb0565","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood-2015-02-626259","article-title":"The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice","volume":"126","author":"Cui","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0570","doi-asserted-by":"crossref","first-page":"8058","DOI":"10.1021\/bi700664y","article-title":"Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine","volume":"46","author":"Yang","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.lfs.2025.123536_bb0575","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1021\/bi0618621","article-title":"trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1","volume":"46","author":"Schmidt","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.lfs.2025.123536_bb0580","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejmech.2014.08.068","article-title":"Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A","volume":"86","author":"Vianello","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.lfs.2025.123536_bb0585","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nm.3101","article-title":"Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction","volume":"19","author":"Shi","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2025.123536_bb0590","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.exphem.2018.08.003","article-title":"Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons","volume":"67","author":"Rivers","year":"2018","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0595","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood.2018892737","article-title":"Inhibition of LSD1 by small molecule inhibitors stimulates fetal hemoglobin synthesis","volume":"133","author":"Le","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0600","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026484","article-title":"Histone lysine demethylase inhibitors","volume":"7","author":"Jambhekar","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.lfs.2025.123536_bb0605","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1182\/blood-2015-06-649087","article-title":"EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression","volume":"126","author":"Renneville","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0610","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00277-020-04136-w","article-title":"UNC0638 induces high levels of fetal hemoglobin expression in \u03b2-thalassemia\/HbE erythroid progenitor cells","volume":"99","author":"Nualkaew","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.lfs.2025.123536_bb0615","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nchembio.599","article-title":"A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells","volume":"7","author":"Vedadi","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.lfs.2025.123536_bb0620","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1021\/acsomega.0c04710","article-title":"Mimicking H3 substrate arginine in the design of G9a lysine methyltransferase inhibitors for cancer therapy: a computational study for structure-based drug design","volume":"6","author":"Chandar Charles","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.lfs.2025.123536_bb0625","first-page":"537","article-title":"Reawakening of human fetal hemoglobin and an epigenetic path to the clinic for sickle cell disease and beta-thalassemia: identification of an orally-available, potent, and selective euchromatic histone lysine methyltransferase 1 and 2 (EHMT1\/2) inhibitor","volume":"130","author":"Chan-Penebre","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2025.123536_bb0630","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1021\/acs.jmedchem.8b02008","article-title":"Discovery of a novel chemotype of histone lysine methyltransferase EHMT1\/2 (GLP\/G9a) inhibitors: rational design, synthesis, biological evaluation, and co-crystal structure","volume":"62","author":"Milite","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2025.123536_bb0635","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1021\/acs.jmedchem.2c02059","article-title":"Discovery of novel substrate-competitive lysine methyltransferase G9a inhibitors as anticancer agents","volume":"66","author":"Nishigaya","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525001705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525001705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:10:20Z","timestamp":1762211420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320525001705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":127,"alternative-id":["S0024320525001705"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2025.123536","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A critique review of fetal hemoglobin modulators through targeting epigenetic regulators for the treatment of sickle cell disease","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2025.123536","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123536"}}